Medicare AdvantageCoverageMedium impact
MA06.029b, Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, and Antiepileptics
Independence Blue Cross·Psychiatry, Neurology, Pharmacy·Pharmacy
Effective date
Jun 25, 2025
We identified it
Jun 19, 2026
Summary
Policy MA06.029b was reissued on 06/25/2025 regarding therapeutic drug monitoring (TDM) for antidepressants, antipsychotics, and antiepileptics. The billing team must review this pharmacy policy to determine if TDM lab codes require prior authorization, documentation requirements, or coverage limitations under Medicare Advantage plans. Specific billing code impacts cannot be determined without access to the full policy text.
Action Required
By 06/25/2025: Billing team must obtain and review the complete MA06.029b policy text from the provided URL. Identify: (1) which CPT codes for TDM labs are affected (e.g., drug level testing codes), (2) whether prior authorization is required for antidepressant, antipsychotic, or antiepileptic TDM testing, (3) any documentation requirements from ordering providers, and (4) coverage limitations or frequency restrictions. Update billing system edits, prior auth workflows, and provider communication materials accordingly. Contact payer at IBX if policy text is not accessible. Failure to implement required prior auth or documentation will result in claim denials for affected TDM services.